Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + anlotinib in second-line unresectable or metastatic soft tissue sarcoma and osteosarcoma
ChiCTR2100055071Phase 2Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and anlotinib in soft tissue sarcoma (STS) and osteosarcoma (OS), sponsored by Shandong Cancer Hospital. Primary endpoint: Objective response rate. Started Jan 2022; status: recruiting.
02
Drugs
sintilimabanlotinib
03
Conditions
soft tissue sarcoma (STS)osteosarcoma (OS)
Beyond the preview
Go deeper on ChiCTR2100055071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100055071.